Embryotoxicity of methylparaben to zebrafish (Danio rerio) early-life stages

Methylparaben (MeP) is widely used as preservative in personal care products, food commodities and pharmaceuticals due to its antimicrobial properties. Its widespread use resulted in the contamination of aquatic environment and raised concerns about the potential adverse effects on human health, especially in the developing organisms. The aim of the present study was to evaluate the embryotoxicity of MeP in zebrafish early-life stages applying the benchmark-dose (BMD) methodology to Fish embryo acute toxicity (FET) tests-OECD guideline 236. Toxic effects were studied by daily evaluation of lethal endpoints, hatching rate and sublethal alterations. Zebrafish fertilized eggs were exposed until 96 h post fertilization (hpf) to five concentrations of MeP: 1 mg/L, 10 mg/L, 30 mg/L, 60 mg/L and 80 mg/L. The lethal concentration 50 (LC 50) was 72.67 mg/L. Indeed, BMD confidence interval (lower bound, BMDL-upper bound, BMDU) was 40.8-57.4 mg/L for lethal endpoints and 16-26.5 mg/L for toxicity index, that includes both lethal and sublethal alterations. Zebrafish embryos exposed to MeP developed sublethal alterations including pericardial edema, yolk edema, blood stasis, reduction in blood circulation, reduced heartbeat and notochord curvature. The number of embryos exposed to the highest concentrations of MeP that reported sublethal alterations increased between 24hpf and 48 hpf-72 hpf-96 hpf. Only zebrafish larvae treated with 30 mg/L of MeP showed behavioural changes. This study highlighted the detrimental effects of MeP on zebrafish early-life stages with attention to its developmental toxicity.

Benchmark dose profiles for joint-action continuous data in quantitative risk assessment

Benchmark analysis is a widely used tool in biomedical and environmental risk assessment. Therein, estimation of minimum exposure levels, called benchmark doses (BMDs), that induce a prespecified benchmark response (BMR) is well understood for the case of an adverse response to a single stimulus. For cases where two agents are studied in tandem, however, the benchmark approach is far less developed. This paper demonstrates how the benchmark modeling paradigm can be expanded from the single-agent setting to joint-action, two-agent studies. Focus is on continuous response outcomes. Extending the single-exposure setting, representations of risk are based on a joint-action dose-response model involving both agents. Based on such a model, the concept of a benchmark profile-a two-dimensional analog of the single-dose BMD at which both agents achieve the specified BMR-is defined for use in quantitative risk characterization and assessment.